论文部分内容阅读
观察吉西他滨联合顺铂(DDP)方案治疗蒽环类和(或)紫杉类耐药转移性乳腺癌的疗效和不良反应。采用吉西他滨联合DDP方案治疗蒽环类和(或)紫杉类均耐药转移性乳腺癌患者52例。吉西他滨1000mg/m2,静脉滴入,d1,d8;DDP25mg/m2,静脉滴入,d1～d3。21d为1个周期,至少用2个周期。本组患者治疗有效率为44.2%(23/52),中位生存时间11.0个月,中位疾病进展时间为5.3个月,1年生存率为42.3%。主要不良反应为胃肠道反应和骨髓抑制。Ⅲ～Ⅳ度呕吐发生率为28.9%(15/52)。Ⅲ～Ⅳ度中性粒细胞减少发生率为15.4%(8/52),Ⅲ～Ⅳ度血小板减少发生率为17.3%(9/52)。初步研究结果显示,吉西他滨联合DDP方案治疗蒽环类和(或)紫杉类均耐药的转移性乳腺癌疗效较好,毒副反应可耐受,是蒽环类及紫杉类耐药的转移性乳腺癌的有效选择。
To observe the efficacy and side effects of gemcitabine combined with cisplatin (DDP) in the treatment of anthracycline and (or) taxane resistant metastatic breast cancer. Gemcitabine combined with DDP regimen in 52 patients with anthracycline and (or) taxane-resistant metastatic breast cancer. Gemcitabine 1000mg / m2, intravenous infusion, d1, d8; DDP25mg / m2, intravenous infusion, d1 ~ d3.21d for a period of at least 2 cycles. The effective rate of treatment in this group was 44.2% (23/52), the median survival time was 11.0 months, the median disease progression time was 5.3 months, and the 1-year survival rate was 42.3%. The main adverse reactions were gastrointestinal reactions and myelosuppression. The incidence of grade Ⅲ ~ Ⅳ vomiting was 28.9% (15/52). The incidence of Ⅲ ~ Ⅳ neutropenia was 15.4% (8/52), and the incidence of Ⅲ ~ Ⅳ thrombocytopenia was 17.3% (9/52). Preliminary studies have shown that gemcitabine combined with DDP regimen for the treatment of anthracycline and (or) taxane-resistant metastatic breast cancer has better efficacy and tolerability, anthracyclines and taxanes resistant An effective choice for metastatic breast cancer.